Open Journal of Epidemiology, 2018, 8, 226-241
Abstract
Introduction: Road traffic accidents (RTAs) are a major public health issue
in developing countries, where roads tend to be built haphazardly and accidents
take a heavy toll on victims—including leaving them disabled. This
study seeks ...to identify those factors that cause RTA victims to become disabled
as a result of their injuries. Methods: This retrospective community-
based study looked at RTA victims treated in five public and faith-based
hospitals in Benin. Disability was evaluated using the Washington Group on
Disabilities Statistics questionnaire. The independent variables were related to
the victim’s socio-demographic traits, the circumstances of the accident, and
post-crash response mechanisms. The proportions were compared using the
chi-squared test, with a threshold of 5%. Results: The prevalence of disability
among road traffic accident victims is 9.59% (CI 95%: 6.86% - 13.20%). The
occurrence of disability is associated with age (p = 0.002), occupational group
(p = 0.0077), the mode of transport used to transfer the victim (p < 0.001)
and the location of the injuries (p = 0.0035). The study also found that people
fail to make sufficient use of post-crash response mechanisms. Conclusion:
Public policy-makers should therefore focus on stepping up interventions to
get more people using both protective equipment and post-crash response services.
more
Les personnes handicapées sont confrontées à des besoins spécifiques auxquels la communauté n’accorde pas toute l’attention requise. Un nombre important de cette couche vulnérable vit dans des conditions déplorables, à la limite déshumanisantes.
Par ses propriétés thérapeutiques, le médicament permet aux professionnels de santé
ainsi quaux pouvoirs publics dassurer la santé des populations. De ce fait, sa disponibilité et
son efficacité sont essentielles et sont le résultat dun circuit complexe (de sa fabrication... à sa
destruction en passant par sa distribution).
Laccessibilité au médicament est un élément déterminant de toute politique de santé.
Elle est garantie par la politique pharmaceutique de chaque pays qui vise à rendre le
médicament disponible pour tous, sur lensemble du territoire (accessibilité géographique), à
tout moment (accessibilité physique), à un prix abordable (accessibilité financière) et en
garantissant son efficacité et sa qualité (accessibilité qualitative
more
Agodokpessi et al. Journal of Pharmaceutical Policy and Practice (2015) 8:12DOI 10.1186/s40545-015-0033-7
Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated
the operation of the RDF and assessed whether there was interruption of supply of asthma me...dicine from 2008 to
2013.
more
Int J Health Policy Manag 2017, 6(10), 587–600
Low-income countries face many contextual challenges to manage healthcare technologies effectively, as the majority are imported and resources are constrained to a greater extent. Previous healthcare technology management (HTM) policies in Benin ha...ve failed to produce better quality of care for the population and cost-effectiveness for the government. This study aims to identify and assess the main problems facing HTM in Benin’s public health sector, as well as the ability of key actors within the sector to address these problems.
more
Journal des anthropologues n° 138-139, 2014
http://journals.openedition.org/jda/4444
Le médicament pharmaceutique industriel est un objet de santé
à la fois scientifique, populaire et marchand. Si ces deux premiers
caractères sont souvent mis en avant respectivement par les sciences
biom...édicales et pharmaceutiques, par la santé publique ainsi qu’à
travers les médias, sa troisième composante est plus souvent passée
sous silence. Elle tend à être dissimulée derrière ce qui est présenté
comme la vocation première du médicament, à savoir la santé des
individus, leur bien-être physique et psychique. Or, le caractère
marchand du médicament est un formidable vecteur de dynamiques
et d’initiatives. Il est peut-être ce qui explique avant tout
l’incroyable vitalité du secteur pharmaceutique de par la planète,
non sans poser de nombreux problèmes d’ordre sanitaire et de santé
publique.
more
Gestion de la Pharmacie dans les Centres de Santé au niveau périphérique
HIV drug resistance , Users Manual
December 2017
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Guidelines
June 2017
HIV strategic information for impact
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0183‐060‐00 WHO
PQ Public Report
October/2016, version 5.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01